Orchard Therapeutics plc American Depositary Shares
ORTX
ORTX was delisted on the 23rd of January, 2024.
33 hedge funds and large institutions have $26.2M invested in Orchard Therapeutics plc American Depositary Shares in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 6 closing their positions.
43% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 7
6% less funds holding
Funds holding: 35 → 33 (-2)
16% less capital invested
Capital invested by funds: $31.2M → $26.2M (-$5M)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $28K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$4.46M |
| 2 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$659K |
| 3 |
Mariner
Overland Park,
Kansas
|
+$347K |
| 4 |
Renaissance Technologies
New York
|
+$174K |
| 5 |
Stifel Financial
St. Louis,
Missouri
|
+$145K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$7.22M |
| 2 |
Citigroup
New York
|
-$854K |
| 3 |
KI
Kapitalo Investimentos
Sao Paulo,
Brazil
|
-$769K |
| 4 |
Temasek Holdings
Singapore
|
-$405K |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
-$269K |
ORTX Hedge Fund Activity: Q2 2023 in Review
33 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Orchard Therapeutics plc American Depositary Shares (ORTX) for Q2 2023, worth a combined $26.2M — down 16% from $31.2M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ORTX and 4 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 10 added.
The largest buyer was Deep Track Capital, adding an estimated $4.46M. The largest seller was Federated Hermes, cutting an estimated $7.22M.
- 33 institutional investors held Orchard Therapeutics plc American Depositary Shares (ORTX) as of Q2 2023, down from 35 in Q1 2023.
- Funds reported $26.2M of Orchard Therapeutics plc American Depositary Shares stock for Q2 2023, down 16% quarter-over-quarter.
- 4 funds opened new Orchard Therapeutics plc American Depositary Shares positions in Q2 2023 and 6 closed out, a net change of -2 holders.
- The largest Orchard Therapeutics plc American Depositary Shares buyer in Q2 2023 was Deep Track Capital, an estimated $4.46M added.
- The largest Orchard Therapeutics plc American Depositary Shares seller in Q2 2023 was Federated Hermes, an estimated $7.22M sold.
Based on aggregated 13F filings for Q2 2023.